Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06895499

Efficacy, Safety, and Tolerability of HB0043 in Hidradenitis Suppurativa Patients.

The purpose of this study is to assess efficacy safety and tolerability of HB0043 in adult patients with moderate to severe HS.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Hidradenitis Suppurativa Bacterial Infections Bacterial Infections and Mycoses Hidradenitis Infections Skin Diseases Skin Diseases, Bacterial Skin Diseases, Infectious Skin and Connective Tissue Diseases Suppuration Sweat Gland Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Dermatology Hospital affiliated to Shandong First Medical University

Jinan, Shandong, China

Location status: Recruiting

Location contact

Wu

CONTACT

[email protected]

+86-15040367023

About this study

The total duration of the study is 28 weeks and consists of: Screening (up to 4 weeks), Treatment Period (20 weeks) and Safety Follow-Up (treatment-free follow-up for 4 weeks).

Participants who prematurely discontinue study treatment are encouraged to remain in the study. Participants who do not wish to remain in the study will enter a 4-week Safety Follow-Up period.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 1. Understand the research procedure of this study and provide written informed consent; 2. Male or female, age 18 years or greater; 3. Diagnosis of HS with a disease duration of at least 6 months before screening; 4. Moderate to severe HS, concurrently meeting the following three criteria:
  • HS lesions in at least 2 distinct anatomic area;
  • One of the HS lesions must be Hurley Stage II or Hurley Stage III;
  • Total abscess and inflammatory nodule (AN) count of greater than or equal to 3; 5. Acceptance by the patient, of childbearing age, to use safe contraceptive methods throughout the study, including six months of follow-up.

Exclusion criteria

  • 1. Participants with known hypersensitivity to HB0043 or any of its excipients; 2. Participant has a draining fistula count of ≥20 at the Screening Visit; 3. Presence of other active autoimmune diseases except HS, including but not limited to psoriasis, psoriatic arthritis, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel disease, and uveitis; 4. Participant has any other active skin disease or condition that may interfere with the assessment of hidradenitis suppurativa; 5. History of lymphoproliferative disorders or any known malignancy within five years prior to the Screening Visit (excluding treated and cured cutaneous squamous cell carcinoma, basal cell carcinoma, carcinoma uterine in situ, or intraductal breast cancer in situ); 6. History of recurrent or recent serious infection; 7. Participant has active tuberculosis (TB) or concurrent treatment for latent TB or evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection; 8. Pregnant or lactating women; 9. Any reason why, in the opinion of the investigator, the patient should not participate.

Treatment and study plan

HB0043

Drug

Low dose

Primary outcomes

  1. Safety and Tolerability of HB0043 in Patients with Moderate to Severe HS

    Time frame: From randomization to end of study, assessed up to 24 weeks.

    The incidence rate, characteristics, relevance, and severity of treatment-emergent adverse events (TEAEs) experienced by subjects during the treatment period.

Secondary outcomes

  1. Percentage of participants achieving HiSCR

    Time frame: Week 16 and 24

    Percentage of participants achieving HiSCR at Week 12 was reported. For this score participants were defined as achievers or non-achievers. The positive HiSCR score was defined as a greater than or equal to (>=) 50% reduction in inflammatory lesion AN count (sum of abscesses and inflammatory nodules), and no increase in abscesses or draining fistulas in hidradenitis suppurativa compared with the lesions counted on visit 1 (baseline).

  2. Change From Baseline in Inflammatory Lesion (Abscesses and Inflammatory Nodules) Count

    Time frame: Week 16 and 24

    The sum of abscesses and inflammatory nodules was measured for each participant to assess change in inflammatory lesion counts.

  3. Change From Baseline in the number of lesions

    Time frame: Week 16 and 24

    The number of lesions refers to the total sum of abscesses, iInflammatory nodules, and draining fistulas count.

  4. Percentage of Participants Achieving ≥ 30% Reduction and ≥ 1 Unit Reduction From Baseline in PGA-NRS

    Time frame: Week 16 and 24

    PGA-NRS is evaluated based on worst skin pain in a 24-hour recall period (maximal daily pain), ranging from 0 (no skin pain) to 10 (skin pain as bad as you can imagine). The percentage of participants who achieved at least 30% reduction and at least 1 unit reduction from Baseline in the PGA-NRS.

  5. Percentage of participants achieving HiSCR75

    Time frame: Week 16 and 24

    HiSCR75 is defined as at least a 75% reduction from Baseline in the total abscess and inflammatory nodule [AN] count, with no increase from Baseline in abscess or draining tunnel count

  6. Change in absolute score from Baseline in International Hidradenitis Suppurativa Severity Score System (IHS4)

    Time frame: Week 16 and 24

    Change from baseline in IHS4. IHS4 score is calculated by the number of nodules (multiplied by 1) + the number of abscesses (multiplied by 2) + the number of draining tunnels (multiplied by 4).

    A total score of 3 or less signifies mild, 4-10 signifies moderate and 11 or higher signifies severe disease.

  7. Serum HB0043 concentrations throughout the study

    Time frame: From randomization to end of study, assessed up to 24 weeks.

  8. Incidence of anti-HB0043 antibody positive response throughout the study

    Time frame: From randomization to end of study, assessed up to 24 weeks.

  9. Percentage of participants achieving HiSCR90

    Time frame: Week 16 and 24

    HiSCR90 is defined as at least a 90% reduction from Baseline in the total abscess and inflammatory nodule [AN] count, with no increase from Baseline in abscess or draining tunnel count

  10. Percentage of participants achieving HiSCR100

    Time frame: Week 16 and 24

    HiSCR100 is defined as at least a 100% reduction from Baseline in the total abscess and inflammatory nodule [AN] count, with no increase from Baseline in abscess or draining tunnel count

  11. Change of the most severe Patient's Global Assessment of Skin Pain (PGA Skin Pain) within the past 24 hours

    Time frame: Week 16 and 24

    The change from baseline in the most severe PGA Skin Pain (NRS score) within the past 24 hours

  12. Dermatology Life Quality Index (DLQI)

    Time frame: Week 16 and 24

    Percentage of participants achieving a DLQI total reduction of ≥4 minimal clinically important difference among participants with a baseline DLQI ≥4. DLQI produces a numeric score that can range from 0 to 30. A higher score indicates greater health related quality of life impairment.

  13. hange of Hidradenitis Suppurativa Area and Severity Index Revised (HASI-R)

    Time frame: Week 16 and 24

    Change from baseline in HASI-R

  14. Change of HIDRA score

    Time frame: Week 16 and 24

    Change from baseline in HIDRA score

  15. Long-term efficacy of sonelokimab: Hidradenitis Suppurativa Quality of Life (HiSQOL)

    Time frame: Week 16 and 24

    Change from baseline in HiSQOL total score

  16. Change of Numerical Rating Scale (NRS)

    Time frame: Week 16 and 24

    Percentage of participants achieving a ≥3-unit reduction from baseline in the NRS

  17. Pharmacodynamic indicators include but are not limited to IL-17 and IL-36.

    Time frame: From randomization to end of study, assessed up to 24 weeks.

Sponsors and collaborators

Lead sponsor

Shanghai Huaota Biopharmaceutical Co., Ltd.

Industry

Collaborators

  • Dermatology Hospital affiliated to Shandong First Medical University

Registry information

Official study title

A Phase I/II, Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety and Efficacy of HB0043 (Bispecific Antibody Targeting IL-17A and IL-36R) in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (HS).

Acronym: HB0043-HS-0-01

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Mar 26, 2025
Registry last updated
Jan 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.